12 Results for "

CDK2/4-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "CDK2/4-IN-1" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-159155
Target:  

CDK Microtubule/Tubulin

Research Areas:  

Cancer

CDK2/4-IN-1 (compound B-4a) is a CDK2/4 inhibitor and a tubulin polymerization inhibitor. CDK2/4-IN-1 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-148065
CAS No.: 2769753-07-1
Purity:  98.77%
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
loading...
    loading...
Cat. No.: HY-173124
Target:  

CDK VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .
loading...
    loading...
Cat. No.: HY-153221
CAS No.: 2845096-18-4
Target:  

CDK

Research Areas:  

Cancer

QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-161595
CAS No.: 1212711-91-5
Target:  

CDK GSK-3

Research Areas:  

Cancer

CDK5-IN-4 (compound 4) is a potent multikinase type-II inhibitor targeting CDK5, with an IC50 of 9.8 μM. CDK5-IN-4 also inhibits GSK-3α, GSK-3β, CDK9, and CDK2, with IC50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. CDK5-IN-4 can be used for glioblastoma research .
loading...
    loading...
Cat. No.: HY-146253
CAS No.: 2414633-49-9
Research Areas:  

Cancer

CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78 and 0.87 μM for CDK1, CDK2 and CDK4, respectively. CDK1/2/4-IN-1 arrests cell cycle at G2/M phase and induces apoptosis. CDK1/2/4-IN-1 elevates Bax, caspase-3, P53 levels and decreases Bcl-2 level. CDK1/2/4-IN-1 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-155602
CAS No.: 364735-73-9
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC50s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .
loading...
    loading...
Cat. No.: HY-160941
CAS No.: 247149-58-2
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-29 (Compound 13q) is an inhibitor for cyclin-dependent kinase (CDK), with IC50 of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively .
loading...
    loading...
Cat. No.: HY-W1047040
CAS No.: 1211585-07-7
Research Areas:  

Cancer

CDK2/4 ligand 1 is a ligand for target protein for PROTACs, which targets CDK2/4. CDK2/4 ligand 1 can be used for synthesis of PROTAC CDK2/4 Degrader-1 (HY-179688) .
loading...
    loading...
Cat. No.: HY-179688
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK2/4 Degrader-1 is a PROTAC degrader of cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4 (CDK4). PROTAC CDK2/4 Degrader-1 induces degradation via the ubiquitin-proteasome pathway. PROTAC CDK2/4 Degrader-1 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-W883326
CAS No.: 2913408-82-7
Target:  

Ligands for E3 Ligase

Research Areas:  

Others

CRBN ligand-902 is a CRBN E3 ligase ligand that can be used for synthesis of PROTAC CDK2/4 Degrader-1 (HY-179688) .
loading...
    loading...
Cat. No.: HY-183273
CAS No.: 3087270-50-3
Research Areas:  

Cancer

BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
  • 1